From: Clinical and molecular characterization of HER2amplified-pancreatic cancer
Clinicopathological characteristics | Total cohort, n = 469 | HER2 amplification | P-value | |
---|---|---|---|---|
 |  | Amplified, n = 10 | Non-amplified, n = 459 |  |
Sex, n (%) | Â | Â | Â | Â |
 Male | 241 (51) | 6 (60) | 220 (51) | 0.7520b |
 Female  | 228 (49) | 4 (30) | 210 (49) | |
Age, years | Â | Â | Â | Â |
 Mean | 66 | 64 | 66 | 0.5467c |
 Median | 68 | 69.5 | 67.5 | |
 Range | 28 to 88 | 47 to 73 | 28 to 87 | |
AJCC stage, n (%) | Â | Â | Â | Â |
 1a | 17 (3.6) | 1 (10) | 16 (3.5) | 0.4495d |
 1b | 25 (5.3) | 1 (10) | 24 (5.2) | |
 2a | 132 (28.1) | 3 (30) | 129 (28) | |
 2b | 279 (59.5) | 4 (40) | 275 (60) | |
 4 | 16 (3.4) | 1 (10) | 15 (3) | |
T stage, n | Â | Â | Â | Â |
 T1 | 32 | 1 | 31 |  |
 T2 | 64 | 2 | 62 |  |
 T3 | 372 | 7 | 365 |  |
 T4 | 1 | 0 | 1 |  |
N stage, n | Â | Â | Â | Â |
 N0 | 180 | 6 | 174 |  |
 N1 | 289 | 4 | 185 |  |
AJCC grade, n | Â | Â | Â | Â |
 1 (well differentiated) | 36 | 0 | 36 | 0.1259d |
 2 (moderately differentiated) | 305 | 10 | 295 | |
 3 (poorly differentiated) | 125 | 0 | 125 | |
 4 (undifferentiated) | 3 | 0 | 3 | |
Tumour size, mm | Â | Â | Â | Â |
 <=20 | 105 | 3 | 102 | 0.4695b |
 >20 | 364 | 7 | 357 | |
Vascular invasion, n | Â | Â | Â | Â |
 Present | 222 | 2 | 220 | 0.1106b |
 Absent | 247 | 8 | 239 | |
Perineural invasion, n | Â | Â | Â | Â |
 Present | 339 | 8 | 331 | 0.7336b |
 Absent | 130 | 2 | 128 | |
Tumour location, n | Â | Â | Â | Â |
 Head | 381 | 9 | 372 | 0.6961b |
 Others | 88 | 1 | 87 | |
 Margins |  |  |  |  |
 Clear | 301 | 7 | 294 | 1.0000b |
 Involved | 168 | 3 | 165 | |
Outcome | Â | Â | Â | Â |
 Follow-up, months  | 0.03 to 240 | 5.0 to 43.6 | 0.03 to 240 | 1.0000b |
 Median follow-up, months  | 16 | 23 | 16 | |
 Death: PDAC | 369 | 8 | 361 | |
 Death: other | 32 | 2 | 30 | |
 Death: unknown | 16 | 0 | 16 | |
 Alive | 49 | 0 | 49 | |
 Lost to follow-up | 3 | 0 | 3 | |
Cancer-specific survival, mean ± SD |  |  |  |  |
 Length, months | 20 ± 19.43 | 28 ± 19.65 | 20 ± 19.55 | 0. 2502c |
Recurrence | Â | Â | Â | Â |
 Present | 261 | 8 | 253 |  |
 Absent | 78 | 1 | 77 |  |
 Unknown | 130 | 1 | 129 |  |
Pattern of recurrence, n (% of total n) | Â | Â | Â | Â |
 Lung without liver metastasis | 22 (8.4% of 261) | 4 (50% of 8) | 18 (7.1% of 253) | 0.0022b |
 Any recurrence without liver metastasis | 127 (49% of 261) | 8 (100% of 8) | 119 (47% of 253) | 0.0028b |
Adjuvant therapy, n | Â | Â | Â | Â |
 Yes | 175 | 3 | 172 |  |
 No | 289 | 7 | 282 |  |
 Unknown | 5 | 0 | 5 |  |